ArticlePharmacoEconomics2025

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection.

Florian Zeevat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.